Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus SANCTURA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus SANCTURA XR.
DETROL vs SANCTURA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Trospium is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, reducing bladder detrusor muscle contractions.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
60 mg orally once daily, taken with a full glass of water at least 1 hour before meals. Extended-release capsule.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal elimination half-life is approximately 7-10 hours in patients with normal renal function; prolonged to 20-30 hours in moderate to severe renal impairment.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Primarily renal excretion (70-80% as unchanged drug and active metabolite); approximately 10% fecal; 5-10% biliary.
Category C
Category C
Anticholinergic
Anticholinergic